Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Drops By 97.4%

Pulmatrix, Inc. (NASDAQ:PULM) saw a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 400 shares, a drop of 97.4% from the February 29th total of 15,300 shares. Based on an average trading volume of 17,900 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Pulmatrix Price Performance

Shares of NASDAQ PULM traded up $0.13 during midday trading on Thursday, reaching $1.75. 38,150 shares of the stock traded hands, compared to its average volume of 17,331. The stock has a market capitalization of $6.39 million, a PE ratio of -0.40 and a beta of 0.95. The company’s 50 day moving average is $1.80 and its 200 day moving average is $1.91. Pulmatrix has a one year low of $1.55 and a one year high of $3.15.

Institutional Trading of Pulmatrix

Several hedge funds have recently made changes to their positions in PULM. Renaissance Technologies LLC increased its stake in Pulmatrix by 7.3% during the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 8,300 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Pulmatrix during the 2nd quarter valued at approximately $141,000. Mariner LLC bought a new position in shares of Pulmatrix during the 4th quarter valued at approximately $97,000. Susquehanna International Group LLP purchased a new stake in Pulmatrix during the 1st quarter valued at $73,000. Finally, Vanguard Group Inc. lifted its position in Pulmatrix by 62.9% in the fourth quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock worth $65,000 after buying an additional 13,548 shares during the last quarter. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Pulmatrix in a research note on Saturday, March 23rd. They issued a “hold” rating for the company.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.